Compugen Ltd. Company Profile
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company primarily focuses on immune checkpoint target candidates to serve as drug targets for cancer immunotherapies addressing various cancer types and patient populations. Its antibody drug conjugate target candidates include CGEN-15001T, CGEN-15022, CGEN-15029, CGEN-15049, CGEN-15027, CGEN-15052, and CGEN-15092 for immuno-oncology; and therapeutic proteins comprise CGEN-15001 for autoimmune diseases. The company was incorporated in 1993 and is headquartered in Holon, Israel.